Stock analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Shares of NAVB stock opened at $0.00 on Thursday. Navidea Biopharmaceuticals has a 12 month low of $0.00 and a 12 month high of $0.15. The stock has a market cap of $100,084.00, a price-to-earnings ratio of -0.02 and a beta of 1.47.
About Navidea Biopharmaceuticals
Further Reading
- Five stocks we like better than Navidea Biopharmaceuticals
- Differences Between Momentum Investing and Long Term Investing
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- What is Short Interest? How to Use It
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.